Overview
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
The aim of this study answer the following questions:
- Changes in the mortality risk profile of these patients after treatment administration.
- Baseline characteristics of patients initiating Selexipag.
- Parameters used for risk stratification prior to treatment escalation.
- Events during follow-up.
No comparison group available
Eligibility
Inclusion Criteria:
- They agree to participate in the study by signing an informed consent form
Exclusion Criteria:
- Decline to participate in the study
- Patients living 6 months or less in the reference health area
- Patients with active malignant tumors